Cellular&MolecularImmunology(2012)9,34–44
ß2012CSIandUSTC.Allrightsreserved1672-7681/12$32.00
doc.guandang.net
RESEARCHARTICLE
Anti-cdTCRantibody-expandedcdTcells:abetterchoicefortheadoptiveimmunotherapyoflymphoidmalignancies
JianhuaZhou,NingKang,LianxianCui,DenianBaandWeiHe
Cell-basedimmunotherapyforlymphoidmalignancieshasgainedincreasingattentionaspatientsdevelopresistancetoconventionaltreatments.cdTcells,whichhavemajorhistocompatibilitycomplex(MHC)-unrestrictedlyticactivity,havebecomeapromisingcandidatepopulationforadoptivecelltransfertherapy.WepreviouslyestablishedastableconditionforexpandingcdTcellsbyusinganti-cdT-cellreceptor(TCR)antibody.Inthisstudy,wefoundthatadoptivetransferoftheexpandedcdTcellstoDaudilymphoma-bearingnudemicesignificantlyprolongedthesurvivaltimeofthemiceandimprovedtheirlivingstatus.Wefurtherinvestigatedthecharacteristicsoftheseantibody-expandedcdTcellscomparedtothemorecommonlyused
phosphoantigen-expandedcdTcellsandevaluatedthefeasibilityofemployingtheminthetreatmentoflymphoidmalignancies.SlowbutsustainedproliferationofhumanperipheralbloodcdTcellswasobserveduponstimulationwithanti-cdTCRantibody.Comparedtophosphoantigen-stimulatedcdTcells,theantibody-expandedcellsmanifestedsimilarfunctionalphenotypesandcytotoxicactivitytowardslymphomacelllines.Itisnoteworthythattheanti-cdTCRantibodycouldexpandboththeVd1andVd2subsetsofcdTcells.Theinvitro-expandedVd1Tcellsdisplayedcomparabletumourcell-killingactivitytoVd2Tcells.Importantly,owingtohigherC–Cchemokinereceptor4(CCR4)andCCR8expression,theVd1TcellsweremorepronetoinfiltrateCCL17-orCCL22-expressinglymphomasthantheVd2Tcells.CharacterizingtheperipheralbloodcdTcellsfromlymphomapatientsfurtherconfirmedthattheanti-cdTCRantibody-expandedcdTcellscouldbeamoreefficaciouschoiceforthetreatmentoflymphoidmalignanciesthanphosphoantigen-expandedcdTcells.
Cellular&MolecularImmunology(2012)9,34–44;doi:10.1038/cmi.2011.16;publishedonline13June2011Keywords:adoptivecelltherapy;anti-cdTCRantibody;cdTcells;lymphoidmalignancies;Vd1subset
INTRODUCTION
Conventionaltherapeuticstrategies,includingchemotherapyandradiotherapy,effectivelysuppresslymphoidmalignanciesduringtheinitialtreatments.However,themajorityofpatientsbecomeresistanttothesetherapies.Therefore,othertherapeuticstrategies,suchascell-basedimmunotherapy,areattractingincreasingattention.1Innateimmunecellsarepromisingcandidatesfortumourimmunotherapybecausetheyplayacriticalroleintumourimmunosurveillance.2
cdTcells,whichfunctioninbothinnateandacquiredimmunity,areconsideredtobepotentcandidatesforimmunotherapy.3,4UnlikeconventionalabTcells,cdTcellscanbeactivatedandexpandedbyseveralphosphorylatednon-peptideantigens(phosphoantigens),includingisopentenylpyrophosphate,bromohydrinpyrophosphate,(E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphateandaminobi-sphosphonates.5Phosphoantigen-activatedcdTcellshavealreadybeentestedinseveralclinicaltrials.Considerableanti-tumoureffectswereoftenobtainedwithoutanysignificanttoxicity.Insomeclinicaltrials,thecdT-cellpopulationwasincreasedthroughinvivocdT-cellexpansionuponphosphoantigenadministration.Studiesinpatientswithsolidtumourshavedemonstratedthattreatmentwithbromohy-drinpyrophosphate(IPH1101)incombinationwithlow-doseinter-leukin2(IL-2)issafeandwell-toleratedandinducespotentcdTlymphocyteexpansioninpatients.6Inanotherclinicaltrial,inpatientswithadvancedbreastcancertreatedwithzoledronateandIL-2,astatisticallysignificantcorrelationbetweenclinicaloutcomeandperi-pheralVc9Vd2Tcellnumbersemerged.7Inaddition,thedirecttrans-ferofinvitro-expandedcdTcellshasbeenusedinsomeclinicaltrialsandwasproventobesafe.8–10Inatrialofadoptivetransferofinvitro-expandedcdTcellstonon-smallcelllungcancerpatients,immu-nomonitoringdatashowedthatthenumberofperipheralcdTcellsgraduallyincreasedwithincreasingnumbersofinfusions.10Potentialanti-tumoureffectshavebeenreportedinsomepatients
DepartmentofImmunology,InstituteofBasicMedicalSciences,ChineseAcademyofMedicalSciencesandSchoolofBasicMedicine,PekingUnionMedicalCollege,NationalKeyLaboratoryofMedicalMolecularBiology,Beijing,China
Correspondence:DrWHe,DepartmentofImmunology,InstituteofBasicMedicalSciences,ChineseAcademyofMedicalSciencesandSchoolofBasicMedicine,PekingUnionMedicalCollege,NationalKeyLaboratoryofMedicalMolecularBiology,Beijing100005,China.E-mail:heweiimu@public.bta.net.cn
DrNKang,DepartmentofImmunology,InstituteofBasicMedicalSciences,ChineseAcademyofMedicalSciencesandSchoolofBasicMedicine,PekingUnionMedicalCollege,NationalKeyLaboratoryofMedicalMolecularBiology,Beijing100005,China.E-mail:n.kang@ibms.pumc.edu.cn
Received16March2011;revised28April2011;accepted3May2011
γδ T cells a better choice for the adoptive immunotherapy of lymphoid malignancies_医学_高等教育_教育专区。Anti-γδ TCR antibody-expanded γδ T ...
A therapeutic anti-CD4 monoclonal antibody inhibits T cell receptor signal transduction in mouse_专业资料。维普资讯 http://www.cqvip.com Cieedclora07101)...
Anti-cd TCR antibody-e... 11页 免费 喜欢此文档的还喜欢 Excel表格办公...Plays a role in the regulation of cell proliferation. Detected in blood ...
研究快报? 人外周血俩T细胞的可溶性anti-TCR俩抗体...puritiesandphenotypesoftheexpanded18were cellswereme...dium.Solubleantibodystimulatedtheexpansionofperipheral...
Glioblastoma cells negative for the anti-CD133 antibody_医药卫生_专业资料。Glioblastoma cells negative for the anti-CD133 antibody...
after crosslinking of the T cell antigen receptor (TCR) with antibody npg ...(f) Proliferation of CFSE-labeled CD4+ T cells stimulated with anti-CD3...
T-cell class I and II molecules of DC present proteins better from ...Anti-CD19 (10 ml) or a relevant isotype control antibody was added. ...
recombinant rat; TCR, T-cell receptor *...Perm-a-Sure permeabilisation control antibody FITC,...(10 mg / ml) and soluble anti-CD28 (2 mg ...
Goldschmidt Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell ...
T cells TCR Signal 2 IL-2 or Anti-CD28 ...Phase I/II Studies of Ex vivo Expanded T cells... MIP-1, and RANTES after antibody receptor ...
热门文档